Trade Summary

1 month ago, Schimmelpennink Evert B., serving as Pres, CEO, Secretary at Lenz Therapeutics, Inc. (LENZ), purchased 28,089 shares at $8.95 per share, for a total transaction value of $251,411.00. Following this transaction, Schimmelpennink Evert B. now holds 77,289 shares of LENZ.

This purchase represents a 57.00% increase in Schimmelpennink Evert B.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 30, 2026, 3 days after the trade was made.

Lenz Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.